ATLANTA, GA – – (Globe Newswire – April 9, 2024) – – A shareholder class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT). The lawsuit alleges that Defendants made materially false and misleading statements and/or failed to disclose material adverse information regarding the Company’s business, operations, and compliance policies, including allegations that: (i) Checkpoint had overstated its oversight and/or its establishment of adequate manufacturing standards and controls over its third-party contract manufacturers; (ii) accordingly, there were one or more issues with the Company’s third-party contract manufacturing organization (“CMO”) for cosibelimab; (iii) all the foregoing reduced the likelihood that the FDA would approve the cosibelimab BLA in its present form; and (iv) as a result, the manufacturing, regulatory, and commercial prospects of cosibelimab were overstated.

If you bought Checkpoint shares March 10, 2021 and December 15, 2023, and suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888)-508-6832 or, you may visit the firm’s website at www.holzerlaw.com/case/checkpoint/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is June 4, 2024.